Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.46 |
| ▸ | FNTB | P49356 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA7 | P43166 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3976847 | 0.85 | SMN1; SMN2 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3982536 | 0.84 | TSHR (0.47) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL3975204 | 0.83 | CA12 (0.51) | FNTAFNTBJAK2JAK3CA12 | |
| SCHEMBL3977084 | 0.82 | ALDH1A1 (0.52) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL3976513 | 0.81 | KDM4E (0.47) | NPC1RAB9AMEN1KMT2AGAA | |
| SCHEMBL3978291 | 0.80 | HPGD (0.39) | CA12CA2MAPTNPC1RAB9A | |
| SCHEMBL3974986 | 0.80 | PTGER4 (0.44) | JAK2JAK3ESR1ESR2TP53 | |
| SCHEMBL3973642 | 0.80 | MAPT (0.46) | FNTAFNTBMAPTNPC1RAB9A | |
| SCHEMBL12951733 | 0.78 | CDC7 (0.48) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL3979501 | 0.78 | HPGDS (0.47) | CA12CA1CA2CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100543022-C | 2-furancarboxylic acid hydrazide compound and contain the pharmaceutical composition of this compound | DAINIPPON PHARMACEUTICAL CO (JP) | 2009-09-23 | — | — | CN | disclosed |
| US-7514452-B2 | 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| CN-1628111-A | 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO (JP) | 2005-06-15 | — | — | CN | disclosed |
| EP-1489077-A1 | 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | GLP1R, GCGR, GPR119 | FNTA 2831/4885FNTB 2779/4885JAK2 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.